Irinotecan and bevacizumab in recurrent glioblastoma multiforme

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

(2011) M.-Y. C. Polley et al.   NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

(2010) Tao Xu et al.   BMC CANCER

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma

(2010) Michael T. Milano et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

(2010) Richard M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy

(2009) Jochen Tuettenberg et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

(2008) Hans Skovgaard Poulsen et al.   ACTA ONCOLOGICA

Brain Tumor Imaging in Clinical Trials

(2008) J.W. Henson et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study

(2008) Machteld AG de Vries et al.   Health and Quality of Life Outcomes

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

(2008) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

(2008) Vinay K. Puduvalli et al.   NEURO-ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef

(2008) S. Guiu et al.   REVUE NEUROLOGIQUE

The use and toxicity of steroids in the management of patients with brain metastases

(2008) Alina Sturdza et al.   SUPPORTIVE CARE IN CANCER

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology